Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Read the full article on WikipediaLocally advanced or metastatic breast cancer Clinical criteria: The condition must be hormone receptor positive, AND The condition must be human epidermal growth factor receptor 2 (HER2) negative, AND The condition must be inoperable. Population criteria: Patient must not be premenopausal. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.
“Fulvestrant is an antiestrogen which acts as an antagonist of the estrogen receptor (ER) and additionally as a selective estrogen receptor degrader (SERD). It works by binding to the estrogen receptor and making it more hydrophobic, which makes the receptor unstable and misfold, which in turn leads normal processes inside the cell to degrade it.”
“IMTooltip Intramuscular injection: 40–50 days”
Working under the parallel aged-care framework? Aged-care equivalent →